Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + lenvatinib + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
A combination therapy regimen consisting of the PD-1 inhibitor sintilimab, the multi-kinase inhibitor lenvatinib, and the albumin-bound chemotherapy agent nab-paclitaxel. This triplet combination is being investigated in clinical trials, notably by Zhejiang Cancer Hospital, as a first-line treatment for patients with recurrent or metastatic triple-negative breast cancer (TNBC). Sintilimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses. Lenvatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), and other kinases to inhibit angiogenesis and tumor growth. Nab-paclitaxel is a nanoparticle formulation of paclitaxel that stabilizes microtubules, leading to cell cycle arrest and apoptosis. The combination aims to provide a multi-pronged attack on TNBC by combining immune checkpoint blockade, anti-angiogenesis, and cytotoxic chemotherapy.
- Other names
- sindilimab + lenvatinib + nab-paclitaxelsintilimab + lenvatinib + nab-paclitaxel
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on sintilimab + lenvatinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + lenvatinib + nab-paclitaxel.